IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CORRADINI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 26.021
EU - Europa 25.975
NA - Nord America 22.264
Continente sconosciuto - Info sul continente non disponibili 2.915
SA - Sud America 2.117
AF - Africa 425
OC - Oceania 255
Totale 79.972
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.208
CN - Cina 11.254
DE - Germania 6.445
GB - Regno Unito 5.820
SG - Singapore 5.550
IT - Italia 4.596
BD - Bangladesh 1.917
RU - Federazione Russa 1.815
HK - Hong Kong 1.646
SE - Svezia 1.631
BR - Brasile 1.460
VN - Vietnam 1.236
FR - Francia 1.174
IN - India 1.082
JP - Giappone 855
IE - Irlanda 728
FI - Finlandia 704
CA - Canada 673
TR - Turchia 645
KR - Corea 621
NL - Olanda 599
ES - Italia 575
UA - Ucraina 451
ID - Indonesia 321
AU - Australia 227
CH - Svizzera 216
PL - Polonia 211
EU - Europa 192
CO - Colombia 186
DK - Danimarca 182
AR - Argentina 179
AT - Austria 171
MX - Messico 156
BE - Belgio 148
CI - Costa d'Avorio 106
GR - Grecia 102
PK - Pakistan 98
IQ - Iraq 89
TW - Taiwan 89
TH - Thailandia 83
PH - Filippine 73
SA - Arabia Saudita 69
ZA - Sudafrica 69
PT - Portogallo 66
CZ - Repubblica Ceca 64
EC - Ecuador 64
IL - Israele 56
CL - Cile 51
VE - Venezuela 48
CR - Costa Rica 46
PE - Perù 46
EG - Egitto 45
UZ - Uzbekistan 44
MY - Malesia 43
MA - Marocco 41
NO - Norvegia 41
JO - Giordania 40
IR - Iran 38
RO - Romania 36
UY - Uruguay 34
PY - Paraguay 32
HU - Ungheria 31
TN - Tunisia 31
JM - Giamaica 30
KE - Kenya 28
NZ - Nuova Zelanda 28
HR - Croazia 27
TT - Trinidad e Tobago 25
AZ - Azerbaigian 24
DZ - Algeria 19
LT - Lituania 19
HN - Honduras 18
NP - Nepal 18
SC - Seychelles 17
AE - Emirati Arabi Uniti 16
GT - Guatemala 16
KZ - Kazakistan 15
BO - Bolivia 13
PA - Panama 13
PR - Porto Rico 13
RS - Serbia 13
SN - Senegal 13
BG - Bulgaria 12
DO - Repubblica Dominicana 12
KW - Kuwait 12
LB - Libano 12
AL - Albania 11
SK - Slovacchia (Repubblica Slovacca) 11
BA - Bosnia-Erzegovina 10
GE - Georgia 10
LU - Lussemburgo 10
EE - Estonia 9
LV - Lettonia 9
OM - Oman 9
BB - Barbados 8
BY - Bielorussia 8
GH - Ghana 8
NI - Nicaragua 8
SV - El Salvador 8
SY - Repubblica araba siriana 8
Totale 77.089
Salva come PNG Salva come JPEG
Città #
Beijing 5.578
Southend 4.902
Frankfurt am Main 4.761
Singapore 3.287
Ashburn 2.302
Hong Kong 1.472
Milan 1.342
San Jose 1.275
Chandler 1.237
Council Bluffs 1.049
Seattle 874
Dallas 848
Dublin 720
Santa Clara 720
Princeton 706
Wilmington 691
New York 540
Fairfield 519
Los Angeles 501
Ann Arbor 429
Helsinki 389
Nanjing 375
Bengaluru 366
Shanghai 346
Hefei 343
Lauterbourg 338
Buffalo 336
Woodbridge 336
Guangzhou 315
Jacksonville 315
Ho Chi Minh City 312
Tokyo 310
Dearborn 304
Houston 299
Redmond 295
Hanoi 290
Des Moines 282
Moscow 276
Rome 275
Boardman 222
The Dalles 211
Toronto 204
Columbus 203
Mountain View 202
Cambridge 195
Jakarta 192
Seoul 183
Tianjin 179
Berlin 177
Redwood City 174
São Paulo 174
Chicago 161
Andover 156
Sakarya 156
Hangzhou 146
Munich 146
Jinan 142
Naples 130
Bogotá 122
Sunnyvale 121
Somerville 118
Serra 117
Warsaw 117
Barcelona 116
Madrid 115
Shenyang 113
Shenzhen 113
London 112
Cangzhou 109
Paris 105
Abidjan 104
Turin 103
Vienna 102
Phoenix 100
Hanover 98
Nuremberg 98
Istanbul 94
Nanchang 93
Brussels 89
Changsha 87
Montreal 87
Wuhan 85
Hebei 82
Atlanta 78
San Diego 75
Bologna 74
Sydney 71
Chengdu 70
Washington 70
Zhengzhou 67
Amsterdam 65
Boston 65
Fuzhou 61
Florence 60
Mumbai 60
Dong Ket 57
Kunming 55
Hyderabad 54
Kiez 54
Athens 53
Totale 46.897
Salva come PNG Salva come JPEG
Nome #
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant 4.647
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 2.136
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations 1.886
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial 1.394
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas 931
Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients 831
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma : a randomised, multicentre, phase 3 trial 665
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas 623
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma 573
Autologous transplantation and maintenance therapy in multiple myeloma 484
Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects 479
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression 419
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups 404
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 388
Non-invasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: a pilot study 368
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR 366
Genomic patterns of progression in smoldering multiple myeloma 341
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies : posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery 337
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma 335
High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG) 332
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma : Three-year Follow-up of CASTOR 324
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma 323
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) 322
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia : early assessment can predict long-term outcome after reduced intensity allogeneic transplantation 310
Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients 309
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 309
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma 302
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients 302
SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias 299
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study 297
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse 296
Italian real life experience with brentuximab vedotin : results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma 295
PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study 291
Long term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies 289
CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide 288
Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome 285
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 282
COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA) 280
The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning : a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo 276
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 276
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBC 273
Integration of Transcriptional and Mutational Data Simplifies the Stratification of Peripheral T-Cell Lymphoma 269
Dioxin exposure of human CD34(+) hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects 267
A Compendium of Transcriptional and Mutational Data to Improve the Stratification of Peripheral T-Cell Lymphoma Subtypes 265
Analysis of the genomic lanscape of multiple myeloma highlights novel candidate prognostic markers and disease subgroups 264
Genomic landscape and chronological reconstruction of driver events in multiple myeloma 264
Role of naïve-derived T memory stem cells in T cell reconstitution following allogeneic transplantation 263
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 263
The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era 262
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial 256
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells 255
B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50 254
Peripheral T-Cell Lymphomas Not Otherwise Specified: Potential Novel Molecular Entities Based on Both Tumor and Microenvironment Cellular Components 254
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes 251
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06 248
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation 247
Analysis of different biological factors in patients affected by peripheral T-cell lymphomas not otherwise specified: GATA-3 expression is associated to refractory disease and poor outcome 247
Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified 244
GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes 242
A novel in-house deep sequencing method for non-invasive disease monitoring in multiple myeloma patients 241
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas after Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT 240
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas : long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect 240
Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications 239
Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3 238
Italian real life experience with brentuximab vedotin : results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 237
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab : a 20-year retrospective follow-up study in patients with lymphoma 236
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 236
Non-myeloablative allografting for newly diagnosed multiple myeloma : the experience of the Gruppo Italiano Trapianti di Midollo. 235
Brief chemoimmunotherapy rituximab ®-FND +/- R maintenance is effective and safe newly diagnosed follicular lymphoma elderly patients : an intergruppo italiano linfomi (IIL) randomized trial 233
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 233
Key concepts and critical issues on epoetin and filgrastim biosimilars: a position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation 231
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B-Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial Including Rituximab in the Reduced Intensity Conditioning Regimen 230
Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma 230
Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation 229
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML 229
Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment 228
Long-term outcome of ric-allo SCT for myeloma 227
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 227
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 224
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas : pre-transplant disease status and histotype heavily influence outcome 224
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines 222
Brief chemoimmunoterapy rituximab (R)-FND ± R maintenance as first line treatment in elderly patients with advanced follicular lymphoma (FL) : preliminary analysis of a prospective randomized IIL trial 220
CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) 220
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term 220
Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients 219
Brief chemoimunotherapy with rituximab (R)- Find ± R maintenance as first treatment in adevanced follicular lymphoma (FL) in elderly : preliminary analysis of a prospective randomized trial 218
Haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post transplant cyclophosphamide GVHD prophylaxis 218
Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis : where do we stand? 216
SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma 216
Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles 215
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 215
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey 214
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates 214
Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas 214
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 213
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers 213
A prospective phase II study on tandem autografting-nonmyeloablative allografting for newly diagnosed myeloma : final results of the Gruppo Italiano Trapianto Midollo Osseo 213
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 213
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 212
Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma : long-term outcomes and graft-versus-host disease-free/relapse-free survival 212
Totale 37.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.117
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.117
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.468 0 241 292 271 359 279 452 400 525 408 343 898
2022/20235.771 687 483 486 577 599 1.054 163 356 539 175 415 237
2023/20247.375 240 317 263 310 906 371 858 807 431 775 1.030 1.067
2024/202511.765 845 1.253 779 1.123 778 508 448 1.107 669 912 1.095 2.248
2025/202622.944 2.089 1.339 2.255 1.566 1.939 1.388 2.241 1.237 2.551 1.590 2.518 2.231
2026/20273.004 1.555 1.449 0 0 0 0 0 0 0 0 0 0
Totale 79.972